Literature DB >> 6684128

Immunological characterisation of plasminogen activators in the human vessel wall.

H Ljungnér, L Holmberg, A Kjeldgaard, I M Nilsson, B Astedt.   

Abstract

A histochemical technique was used to identify the activity of the plasminogen activator (PA) in the vessel wall of veins. Antibodies against melanoma cell activator and urokinase (UK), both raised in goats, were mixed into the fibrin film. The PA activity was quenched by the antibodies against melanoma activator but remained unchanged when antibodies against UK, or an IgG preparation of normal goat serum, was mixed in the fibrin film. The results of this study show that the PA activity in the vein vessel wall is immunologically similar to or identical to the PA derived from melanoma cells which has previously been shown to cross-react with the tissue-like PA. No UK-like activity was present in the vessel wall.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684128      PMCID: PMC498466          DOI: 10.1136/jcp.36.9.1046

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

1.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells.

Authors:  D J Loskutoff; T E Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

2.  Purification of urokinase by affinity chromatography.

Authors:  L Holmberg; B Bladh; B Astedt
Journal:  Biochim Biophys Acta       Date:  1976-08-12

3.  Quantitation of fibrinolytic activity in venous and prosthetic arterial grafts.

Authors:  J S Yao; J J Bergan; H C Kwaan
Journal:  Arch Surg       Date:  1974-08

Review 4.  New aspects of the pathogenesis of thrombo-embolism.

Authors:  I M Nilsson; S Isacson
Journal:  Prog Surg       Date:  1973

5.  On release and synthesis of fibrinolytic activators in human organ culture.

Authors:  B Astedt; M Pandolfi
Journal:  Rev Eur Etud Clin Biol       Date:  1972-03

6.  Preparation of plasminogen activator from vascular trees of human cadavers. Its comparison with urokinase.

Authors:  N Aoki
Journal:  J Biochem       Date:  1974-04       Impact factor: 3.387

7.  Differences in the binding to fibrin of urokinase and tissue plasminogen activator.

Authors:  S Thorsen; P Glas-Greenwalt; T Astrup
Journal:  Thromb Diath Haemorrh       Date:  1972-08-31

8.  Fibrinolytic activity of human veins in arms and legs.

Authors:  M Pandolfi; B Robertson; S Isacson; I M Nilsson
Journal:  Thromb Diath Haemorrh       Date:  1968-11-15

9.  Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.

Authors:  B Astedt; L Holmberg
Journal:  Nature       Date:  1976-06-17       Impact factor: 49.962

10.  Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.

Authors:  P M Mannucci; M Aberg; I M Nilsson; B Robertson
Journal:  Br J Haematol       Date:  1975-05       Impact factor: 6.998

View more
  5 in total

1.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

2.  In vitro stimulation of plasminogen activator release from vein walls by adrenaline.

Authors:  A Kjaeldgaard; M Kjaeldgaard
Journal:  J Clin Pathol       Date:  1986-11       Impact factor: 3.411

3.  Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.

Authors:  A Kjaeldgaard; B Larsson; B Astedt
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

4.  Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

Authors:  I M Nilsson; H Ljungnér; L Tengborn
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

5.  Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.

Authors:  A Larsson; B Astedt
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.